Sandostatin LAR (octreotide) Signifor (pasireotide) Signifor LAR (pasireotide) Somatuline Depot (lanreotide) octreotide FDA Approved Indications: Acromegaly: Octreotide Injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. In patients with acromegaly, octreotide reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50% to 60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide; these trials were not optimally designed to detect such effects. Sandostatin LAR Depot is indicated in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated. Somatuline Depot Injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. Signifor LAR is indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Carcinoid Tumors: Octreotide Injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Octreotide studies were not designed to show an effect on the size, rate of growth or development of metastases. Sandostatin LAR Depot is indicated in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated. Vasoactive Intestinal Peptide Tumors (VIPomas): Octreotide Injection is indicated for the treatment of the profuse watery diarrhea associated with VIPsecreting tumors. Octreotide studies were not designed to show an effect on the size, rate of growth or development of metastases. Sandostatin LAR Depot is indicated in patients in whom initial treatment with Sandostatin Injection has been shown to be effective and tolerated. Cushing s Disease: Signifor (but NOT Signifor LAR) is indicated for the treatment of adult patients with Cushing s disease for whom pituitary surgery is not an option or has not been curative. 1
Authorization Guidelines: General Criteria for ALL Indications: Sandostatin LAR: o Baseline A1c or fasting glucose, TSH, and EKG o Positive response to octreotide immediate release injection for at least 2 weeks Somatuline Depot: o Baseline A1c or fasting glucose o Trial and failure of Sandostatin LAR, or intolerance to octreotide or Sandostatin LAR Signifor and Signifor LAR: o Baseline A1c, fasting plasma glucose, EKG, potassium, magnesium, TSH, and LFT s o Trial and failure of Sandostatin LAR, or intolerance to octreotide or Sandostatin LAR Additional criteria for use in Acromegaly (octreotide, Sandostatin LAR, Somatuline Depot, Signifor LAR): Patient is 18 years of age or older Prescribed by, or in consultation with an endocrinologist Patient has persistent disease following pituitary surgery, or surgical resection is not an option as evidenced by one of the following: o Majority of tumor cannot be resected o Patient is a poor surgical candidate based on comorbidities o Patient prefers medical treatment over surgery, or refuses surgery Baseline IGF-1 is >2x ULN for age OR IGF-1 remains elevated despite a 6 month trial of maximally tolerated dose of cabergoline (unless patient cannot tolerate cabergoline or has a contraindication) Additional criteria for use for Carcinoid tumor or VIPomas (octreotide, Sandostatin LAR, Somatuline Depot): Patient is 18 years of age or older Prescribed by, or in consultation with oncologist or endocrinologist Criteria for use for Cushing s Syndrome (Signifor): Patient has persistent disease after pituitary surgery, or surgery is not an option Trial and failure of, or intolerance/contraindication to cabergoline Baseline A1c, fasting plasma glucose, EKG, potassium, magnesium, TSH and LFT s NOTE: Patient does not need a trial of octreotide for approval Additional criteria for off-label use for Hepatorenal syndrome (octreotide): Prescribed by hepatologist or nephrologist Must be used in combination with midodrine and albumin Additional criteria for off-label use for Gastroenteropancreatic neuroendocrine tumor (GEP-NET) (octreotide, Sandostatin LAR, Somatuline Depot): 2
Prescribed by or in consultation with oncologist or endocrinologist Patient has persistent disease after surgical resection, or is not a candidate for surgery Octreotide may be reviewed for medical necessity and may be approved for treatment of the following offlabel indications: Chemotherapy induced diarrhea in pediatrics, when prescribed by or in consultation with oncologist Dumping Syndrome in adults >18 years of age Enterocutaneous fistula in adults >18 years of age Hyperthyroidism due to thyrotropinoma in adults >18 years of age Short bowel syndrome (associated diarrhea) in adults >18 years of age Portal hypertension and/or upper GI bleed related to variceal bleeding in patients with esophageal varices in adults >18 years of age Off-label indications included based on peer-reviewed clinical studies Initial Approval: 6 months Renewal: Acromegaly and Cushing s: Indefinite Carcinoid and VIPomas: Indefinite All other indications: 6 months Clinical documentation required: o Response to therapy and A1c or fasting glucose o For Acromegaly: Decreased or normalized IGF-1 levels o For Carcinoid and VIPomas: Symptom improvement o For Cushing s: Decreased or normalized cortisol levels o For Signifor: LFT s Additional Information: Normal IGF-1 Levels (by age and gender): Females ng/ml Males ng/ml 18 years 109-527 114-493 19 years 104-484 105-441 20 years 98-443 97-398 21-25 years 83-344 84-323 26-30 years 75-275 77-271 31-35 years 71-241 73-244 3
36-40 years 69-226 68-225 41-45 years 64-210 62-205 46-50 years 59-201 56-194 51-55 years 56-201 53-191 56-60 years 51-194 45-173 61-65 years 47-191 41-168 66-70 years 46-195 39-168 71-75 years 42-187 36-166 76-80 years 39-184 35-168 80-85 years 37-182 35-179 85-90 years 35-182 33-179 Pharmacy Prior Authorization References: 1. Sandostatin LAR Depot (octreotide acetate) [package insert]. Schaftenau, Austria: Sandoz; Revised June 2014. 2. Sandostatin (octreotide acetate) [package insert]. West Hartford, CT: Novartis Pharmaceuticals Corporation; Revised March 2012. 3. Signifor LAR (pasireotide) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Revised December 2014. 4. Somatuline Depot (lanreotide) [package insert]. Signes, France: Ipsen Pharma Biotech; Revised December 2014. 5. Pomier-Layrargues G, Paquin SC, Hassoun Z, et al. Octreotide in hepatorenal syndrome: A randomized, doubleblind, placebo-controlled, crossover study. Hepatology. 2003;38:238-243. 6. Tauber MT, Harris AG, Rochiccioli P. Clinical use of the long acting somatostatin analogue octreotide in pediatrics. Eur J Pediatr. 1994;153:304-310. 7. Gray JL, Debas HT, Mulvihill SJ. Control of dumping symptoms by somatostatin analogue in patients after gastric surgery. Arch Surg. 1991;126:1231-1236. 8. Nubiola-Calonge P, Sancho J, Segura M, et al. Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output. Lancet. 1987;2:672-673. 9. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med. 1993;119:236-240. 10. Rosenberg L, Brown RA. Sandostatin in the management of nonendocrine gastrointestinal and pancreatic disorders: a preliminary study. Can Assoc Gen Surg. 1991;34:223-9. 11. Sung JJY, Chung SCS, Lai CE, et al. Octreotide infusion or emergency sclerotherapy for variceal haemorrhage. Lancet. 1993;342:637-41. 12. Kuhn JM, Arlot S, Lefebvre H, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000;85:1487-91. 13. Melmed S. Treatment of acromegaly. Waltham, MA: UptoDate; Last modified May 22, 2015. http://www.uptodate.com/contents/treatment-ofacromegaly?source=search_result&search=acromegaly&selectedtitle=2%7e84. Accessed August 20, 2015. 14. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2015. Available at: www.clinicalpharmacology.com (cited: 08/19/2015). 15. NCCN: National Comprehensive Cancer Network. NCCN Clinical Practice Guideline in Oncology: Neuroendocrine Tumors. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf Version 1.2015. Accessed August 16, 2015. 4
16. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, 2014;99(11):3933 3951. 5